Optimising aerosolized therapies in critically ill patients.

While pulmonary and systemic pharmacokinetic data can guide optimal aerosol drug dosing in the critically ill, there are limited pharmacokinetic-pharmacodynamic data with aerosolized therapy in ICU affecting effective drug dosing. Airway size, nebulizer position, heated humidification (HH), bias flow, and patient-ventilator dyssynchrony are some factors affecting aerosol drug delivery [[1]]. Amongst the machines that help save lives in the intensive care unit (ICU) environment, aerosol drug delivery devices play a special role. Aerosol drug formulations and dosing In ICU, aerosolized drugs consist of specific aerosol formulations, such as bronchodilators and off-label use of intravenous formulations, e.g., tobramycin. [Extracted from the article]